Holen Sie sich die Stockscreener-App
0.9169
0.07%
0.0006
Schlusskurs vom Vortag:
$0.9163
Offen:
$0.92
24-Stunden-Volumen:
654.90K
Relative Volume:
0.22
Marktkapitalisierung:
$55.31M
Einnahmen:
Nettoeinkommen (Verlust:
$-27.37M
KGV:
-2.0143
EPS:
-0.4552
Netto-Cashflow:
$-25.99M
1W Leistung:
-0.74%
1M Leistung:
-31.57%
6M Leistung:
-48.49%
1J Leistung:
-82.99%
1-Tages-Spanne:
$0.882
$0.94
1-Wochen-Bereich:
$0.8619
$0.99
52-Wochen-Spanne:
$0.8619
$5.93
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Firmenname
Aldeyra Therapeutics Inc
Sektor
Branche
Telefon
781-761-4904
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
0.9169 | 55.31M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
507.88 | 128.73B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
215.68 | 86.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
767.17 | 78.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.65 | 51.36B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
190.66 | 40.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-04-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-30 | Eingeleitet | Jefferies | Buy |
| 2020-10-16 | Eingeleitet | BTIG Research | Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-04 | Eingeleitet | Citigroup | Buy |
| 2018-09-26 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Janney | Buy |
| 2018-01-26 | Eingeleitet | Seaport Global Securities | Buy |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-01 | Eingeleitet | Stifel | Buy |
| 2015-07-01 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-03-20 | Bestätigt | H.C. Wainwright | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-06-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye - Streetwise Reports
Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target - Investing.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye DiseaseSlideshow (NASDAQ:ALDX) 2026-09-30 - Seeking Alpha
Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute ResolutionAldeyra Therapeutics (NASDAQ:AL - Benzinga
ALDX Reiterated by BTIG -- Price Target Maintained at $9.00 - GuruFocus
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease - ophthalmologytimes.com
BTIG reiterates Buy rating on Aldeyra Therapeutics, $9 price target - TradingView
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease - Yahoo Finance
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Aldeyra to appeal FDA rejection of dry eye drug reproxalap - Investing.com
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com - Investing.com India
Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease - tradingview.com
After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. - Stock Titan
Aldeyra Therapeutics to Host Regulatory Update Webcast - FinancialContent
Aldeyra Therapeutics to Host Regulatory Update Webcast - Yahoo Finance
Aldeyra Therapeutics Inc (ALDX) Stock Price Target & Forecast - TradingKey
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX: Aldeyra Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-09-06 | Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALDX | Press Release - stockhouse.com
Aldeyra Therapeutics, Inc. (ALDX) Options Chain - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat
AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus
HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - vinanet.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aldeyra Therapeutics Inc-Aktie (ALDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
6.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):